Salvat heads to regulators with phase 3 data on ocular steroid : vimarsana.com

Salvat is gearing up to launch an ocular corticosteroid treatment for inflammation and pain in cataract surgery patients after finishing phase 3 trials and starting the approval process in the U.S.

Related Keywords

, Laboratorios Salvat , Teroids , Ataracts , Ataract Surgery , Cular Drug Delivery , Ionanotechnology , Drug Delivery , Linical Data , Ierce Pharma Homepage , Pharma ,